4-aza steroids
US6365597B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 11, 1997 |
| Grant date | Apr 2, 2002 |
| Priority date | — |
| Expiry date | Feb 11, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D221/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention related to 4-aza-17&bgr;-(cyclopropoxy)-androst-5&agr;-androstan-3-one, 4-aza-17&bgr;-(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20 lyase, 5&agr;-reductase and C17&agr;-hydroxylase and to the use of these compounds in the treatment of androgen and estrogen mediated disorders, including benign prostatic hyperplasia, androgen mediated prostate cancer, estrogen mediated breast cancer and to DHT-mediated disorders such as acne. Disorders relating to the oversynthesis of cortisol, for example, Cushing's Syndrome, are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have the following general formula:
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.